These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Hajishengallis G; Hajishengallis E; Kajikawa T; Wang B; Yancopoulou D; Ricklin D; Lambris JD Semin Immunol; 2016 Jun; 28(3):285-91. PubMed ID: 27021500 [TBL] [Abstract][Full Text] [Related]
7. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. Abe T; Hosur KB; Hajishengallis E; Reis ES; Ricklin D; Lambris JD; Hajishengallis G J Immunol; 2012 Dec; 189(11):5442-8. PubMed ID: 23089394 [TBL] [Abstract][Full Text] [Related]
8. Periodontitis induced by Blasco-Baque V; Garidou L; Pomié C; Escoula Q; Loubieres P; Le Gall-David S; Lemaitre M; Nicolas S; Klopp P; Waget A; Azalbert V; Colom A; Bonnaure-Mallet M; Kemoun P; Serino M; Burcelin R Gut; 2017 May; 66(5):872-885. PubMed ID: 26838600 [TBL] [Abstract][Full Text] [Related]
9. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Maekawa T; Krauss JL; Abe T; Jotwani R; Triantafilou M; Triantafilou K; Hashim A; Hoch S; Curtis MA; Nussbaum G; Lambris JD; Hajishengallis G Cell Host Microbe; 2014 Jun; 15(6):768-78. PubMed ID: 24922578 [TBL] [Abstract][Full Text] [Related]
10. Complement and periodontitis. Hajishengallis G Biochem Pharmacol; 2010 Dec; 80(12):1992-2001. PubMed ID: 20599785 [TBL] [Abstract][Full Text] [Related]
11. Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Hajishengallis G; Kajikawa T; Hajishengallis E; Maekawa T; Reis ES; Mastellos DC; Yancopoulou D; Hasturk H; Lambris JD Front Immunol; 2019; 10():406. PubMed ID: 30915073 [TBL] [Abstract][Full Text] [Related]
12. Fimbrial proteins of porphyromonas gingivalis mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. Wang M; Shakhatreh MA; James D; Liang S; Nishiyama S; Yoshimura F; Demuth DR; Hajishengallis G J Immunol; 2007 Aug; 179(4):2349-58. PubMed ID: 17675496 [TBL] [Abstract][Full Text] [Related]
13. Potential use of gallium-doped phosphate-based glass material for periodontitis treatment. Sahdev R; Ansari TI; Higham SM; Valappil SP J Biomater Appl; 2015 Jul; 30(1):85-92. PubMed ID: 25681404 [TBL] [Abstract][Full Text] [Related]
15. Human β-defensin 3 inhibits periodontitis development by suppressing inflammatory responses in macrophages. Cui D; Lyu J; Li H; Lei L; Bian T; Li L; Yan F Mol Immunol; 2017 Nov; 91():65-74. PubMed ID: 28886588 [TBL] [Abstract][Full Text] [Related]
16. Mouse model of experimental periodontitis induced by Porphyromonas gingivalis/Fusobacterium nucleatum infection: bone loss and host response. Polak D; Wilensky A; Shapira L; Halabi A; Goldstein D; Weiss EI; Houri-Haddad Y J Clin Periodontol; 2009 May; 36(5):406-10. PubMed ID: 19419440 [TBL] [Abstract][Full Text] [Related]
17. Porphyromonas gingivalis virulence factors involved in subversion of leukocytes and microbial dysbiosis. Zenobia C; Hajishengallis G Virulence; 2015; 6(3):236-43. PubMed ID: 25654623 [TBL] [Abstract][Full Text] [Related]
18. [Pathogenic potential of Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia, the red bacterial complex associated with periodontitis]. Bodet C; Chandad F; Grenier D Pathol Biol (Paris); 2007; 55(3-4):154-62. PubMed ID: 17049750 [TBL] [Abstract][Full Text] [Related]
19. Tamibarotene modulates the local immune response in experimental periodontitis. Jin Y; Wang L; Liu D; Lin X Int Immunopharmacol; 2014 Dec; 23(2):537-45. PubMed ID: 25448496 [TBL] [Abstract][Full Text] [Related]
20. Bismuth drugs tackle Porphyromonas gingivalis and attune cytokine response in human cells. Cheng T; Lai YT; Wang C; Wang Y; Jiang N; Li H; Sun H; Jin L Metallomics; 2019 Jul; 11(7):1207-1218. PubMed ID: 31179464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]